Frédéric Baron

Frédéric Baron publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Frédéric Baron sits on this spectrum.

Frédéric Baron D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Frédéric Baron sits on this spectrum.

Best Publications

• Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

  Mohamed L. Sorror;Michael B. Maris;Michael B. Maris;Rainer Storb;Rainer Storb;Frederic Baron

  3159
  Citations

• Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation

  M. Mohty;F. Malard;M. Abecassis;E. Aerts

  586
  Citations

• Comorbidity and Disease Status–Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation

  Mohamed L. Sorror;Brenda M. Sandmaier;Barry E. Storer;Michael B. Maris

  535
  Citations

• Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning

  Frédéric Baron;Michael B. Maris;Brenda M. Sandmaier;Barry E. Storer

  427
  Citations

• Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

  Frédéric Baron;Jennifer E. Baker;Rainer Storb;Theodore A. Gooley

  319
  Citations

• Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.

  Frédéric Baron;Chantal Lechanteur;Evelyne Willems

  294
  Citations

• Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

  Lori Muffly;Marcelo C. Pasquini;Michael Martens;Ruta Brazauskas

  283
  Citations

• Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation

  F. Baron;M. Labopin;D. Niederwieser;S. Vigouroux

  242
  Citations

• Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.

  P. Tsirigotis;M. Byrne;C. Schmid;Frédéric Baron

  231
  Citations

• Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  Sebastian Giebel;Anna Czyz;Oliver Ottmann;Frederic Baron

  220
  Citations

• Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

  Frédéric Baron;B. M. Sandmaier;B. M. Sandmaier

  196
  Citations

• Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

  Alexandros Spyridonidis;Myriam Labopin;Bipin N. Savani;Riitta Niittyvuopio

  187
  Citations

• Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study

  Roni Shouval;Roni Shouval;Myriam Labopin;Ori Bondi;Hila Mishan-Shamay

  182
  Citations

• Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo

  Julia Cuende;Stéphanie Liénart;Olivier Dedobbeleer;Bas van der Woning

  166
  Citations

• Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

  Sebastian Giebel;David I. Marks;Nicolas Boissel;Frederic Baron

  161
  Citations

• Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  Frédéric Baron;Mohamad Mohty;Didier Blaise;Gérard Socié

  155
  Citations

• Hematopoietic cell transplantation (HCT)-specific-comorbidity index: A new tool for risk assessment before allogeneic HCT

  M.L. Sorror;M.B. Maris;M.B. Maris;R.F. Storb;R.F. Storb;F. Baron

  143
  Citations

• Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study.

  Olivier Detry;Morgan Vandermeulen;Marie-Hélène Delbouille;Joan Somja

  137
  Citations

• Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

  Ali Bazarbachi;Gesine Bug;Frederic Baron;Eolia Brissot

  130
  Citations

• Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model

  Céline Grégoire;Caroline Ritacco;Muriel Hannon;Laurence Seidel

  124
  Citations